News

Update on Psychedelics: Science and Capital Markets

CPD Information: 1 Substantive Hour for Lawyers

Nov 23 Update on Psychedelics Science and Capital Markets Website 876x254 Archive

ACCESS ARCHIVE

External Speakers:

Doug Drysdale, CEO - Cybin
Sumant S. Kulkarni, Managing Director - Canaccord Genuity LLC
David Wood, Chief Legal Officer & General Counsel - Psygen

The conversation surrounding psychedelic-assisted therapy as a mental health treatment has skyrocketed over the last year as we witnessed an explosion of new psychedelics companies. The industry is experiencing a rise in public and private financings, mergers and acquisitions and going-public transactions. Companies and academic institutions have formed mutually-beneficial partnerships to fund research, utilize data and protect intellectual property.

As the psychedelics industry continues to expand, what options are available for market participants pursuing new opportunities? How will this affect the domestic and cross-border legal and regulatory landscape? What are the recent scientific advancements regarding the use of psychedelics as medicine?

Join industry experts to learn about recent scientific research, the regulatory landscape and opportunities within capital markets.

For information regarding our webinars and communications, please contact:
Melanie Smilynov | rsvp@airdberlis.com | 416.863.1500 x2457

Should you experience any technical difficulties, we encourage you to review this help link to assist you in having an optimal webinar experience..